Currently, cancer patients and survivors face a significantly increased risk of cardiovascular morbidity and mortality due to the effects of cancer therapies. However, there are no actionable or biologically plausible biomarkers to stratify and manage this risk effectively. The heterogeneity of cancer treatments and their cardiovascular effects complicates risk prediction. Clonal Hematopoiesis of Indeterminate Potential (CHIP) has recently emerged as a novel biomarker that is highly prevalent in cancer populations and linked to increased cardiovascular risk. Despite its promise, knowledge about CHIP and its clinical applications remains limited. This deficit underlies the gap in practice: clinicians cannot yet integrate CHIP into cardiovascular risk assessment for cancer survivors.     

CHIP biology and its health implications are not yet widely understood by clinicians. Emerging data suggest CHIP is particularly prevalent among cancer patients and survivors exposed to cytotoxic therapies such as chemotherapy or radiation. Given that CHIP may serve as a unifying biomarker for cardiovascular complications across diverse cancer therapies, it is essential that healthcare providers become familiar with its biology, prevalence, and implications. Without targeted educational efforts, clinicians may remain unaware of CHIP’s potential role in patient care, slowing the translation of this knowledge into improved cardiovascular risk management in oncology settings.